1. Introduction
Boron neutron capture therapy (BNCT) is a unique radiotherapeutic approach for treating cancer, relying on the
10B(n, α)
7Li nuclear reaction when stable
10B interacts with thermal neutrons. The possibility of exploiting the neutron capture reaction to treat tumors was introduced by Locher in 1936, laying the foundation for the development of boron neutron capture therapy (BNCT) [
1]. The first application of BNCT took place in 1951, targeting a patient with malignant glioma. This groundbreaking endeavor utilized the existing nuclear research reactor at the Brookhaven Graphite Research Reactor [
2]. A comprehensive overview of the state of BNCT based on reactor sources of neutrons was provided in a technical document published by the International Atomic Energy Agency in 2001 [
3]. More recent advances in the field are summarized in a new IAEA report, published in 2023 [
4].
BNCT is particularly promising for treating locally invasive malignant tumors due to the high neutron-capture cross-section of
10B and the short ranges of its resulting alpha particles and recoiling
7Li nuclei [
1]. These high linear energy transfer (LET) particles, with LET values of approximately 150 keVµm
−1 for alpha particles and 175 keVµm
−1 for
7Li nuclei, deposit their energy within a small tissue volume, typically within micrometers. This selective energy deposition offers potential precision in cancer cell destruction while sparing surrounding healthy tissue. The alpha particles and
7Li nuclei have approximate ranges of 4.5 µm and 10 µm [
3,
4].
The key advantage of BNCT lies in the selective uptake of boron-loaded carriers by cancer cells, ensuring a higher concentration of boron atoms in cancerous tissue compared to healthy tissue. This selective uptake enables additional doses from alpha and lithium particles, effectively sterilizing cancer cells while limiting damage to healthy tissue [
5].
BNCT presents several dose components, including the ‘boron dose’ (alpha and lithium-ion disintegration products), fast neutron dose, nitrogen capture proton dose, and gamma doses from the neutron source and from capture and scattering of neutrons in the beam line structures, as well as those produced in the body from hydrogen capture reactions. Accurate dosimetry in BNCT is essential due to its various radiation components. It is also essential to minimize radiation components other than those from thermal neutrons [
3,
4].
Microdosimetry, involving the measurement of various components contributing to the total dose [
6,
7], has emerged as a promising tool for characterizing radiation field quality in BNCT. The first measurements were conducted in 1992 [
6] and subsequently discussed in a review paper [
7]. Since then, both Monte Carlo simulation studies [
8,
9] and experimental measurements using tissue-equivalent proportional counters (TEPCs) have explored microdosimetry in the context of reactor-based BNCT [
10,
11,
12,
13,
14,
15,
16] and accelerator-based BNCT [
17].
Given the diverse aspects of the investigated radiation fields (gamma component, fast neutron component, epithermal/thermal neutron field) and the variations in the employed detectors (different sensitive volume shape, simulated site size, and boron concentration, etc.), the literature microdosimetric distributions are not directly comparable with those presented in this work. However, the measurements by Wuu, Kota, and Burmeister [
6,
10,
11] were conducted at similar site sizes of 2, 0.5, and 1 μm, respectively; therefore, the pure BNC component is expected to be similar to ours.
No measurement has been reported for variable boron concentrations to date. The dose resulting from the boron neutron capture (BNC) reaction is directly proportional to the concentration of 10B. Therefore, adjusting the dose measurement to different concentrations of 10B allows for a more accurate simulation of the realistic situation in the tumor and surrounding healthy tissue.
This study aims to deepen our understanding of boron neutron capture therapy (BNCT) by achieving the following objectives: (1) Verification of the nominal 10B concentration. (2) Optimization of the procedure for determining the BNC component through pairwise microdosimetric measurements. (3) Calculation of the BNC component for varying 10B concentrations.
To accomplish these goals, we utilized a cylindrical tissue-equivalent proportional counter (TEPC) equipped with interchangeable cathode walls doped with
10B atoms at different concentrations (0, 10, 25, 70, and 100 ppm) [
18]. Experimental measurements were conducted at the LNL-INFN accelerator-based BNCT facility available at the Legnaro National Laboratories of the Italian National Institute for Nuclear Physics (LNL-INFN). This is a research-oriented facility capable of delivering a thermal neutron flux of about 4.5 × 10
5 s
−1cm
−2 [
17,
19].
3. Results and Discussion
Figure 4 illustrates microdosimetric frequency distributions, represented as
, acquired under different boron concentrations and in the absence of boron. The left panel employs a logarithmic
x-axis and a linear
y-axis, ensuring that equivalent visual areas under the curves signify identical relative contributions to the total number of events. Notably, around half of the events exhibit lineal energy values below 0.15 keV/µm, with a minimal fraction surpassing 20 keV/µm. Specifically, this fraction is less than 0.1% without
10B and rises to nearly 0.3% at a 100 ppm
10B concentration.
When examining
on a linear scale, the spectra with or without
10B exhibit almost indistinguishable patterns, primarily due to the minor proportion of neutron-capture events involving boron compared to the total events. In the right panel of
Figure 4, a double logarithmic scale is employed to accentuate small distinctions in events occurring above approximately 20 keV/µm. These variations arise from the increasing occurrence of BNC events as the boron concentration increases. Notably, the spectra maintain a consistent shape in the photon region (below 20 keV/µm), indicating minimal additional gamma components introduced by boron doping. This confirms the validity of the adopted procedure for aligning the photon components.
Figure 5 illustrates the dose distributions of the lineal energy at different boron concentrations. The distributions are graphed as
vs.
, with the lineal energy
represented on a logarithmic scale. This graphical representation ensures that the size of the area under the curve between any two
y values corresponds to the dose fraction in that range.
In the left panel of
Figure 5, the
distributions are individually normalized to a unit dose, following the definition of the dose probability density of
, denoted as
[
22]. As the high lineal energy components increase in the boronated spectra, the corresponding gamma components decrease to maintain normalization. It is important to note that this misalignment of the photon regions does not imply a reduction in gamma doses; instead, the gamma doses are expected to remain nearly the same. To address this, the photon regions (i.e., the part of the spectra below approximately 20 keV/µm) of the boronated spectra are aligned with the distribution without
10B by scaling them with constant factors. This scaling, crucial for matching the gamma components, is a necessary step to accurately assess the additional contribution to the dose resulting from the boron neutron capture reaction. Following proper scaling, the process enables the derivation of the pure BNC component by subtracting the boron-free spectrum from the one with boron.
As a result, the scaled distributions for the boronated scenarios lose normalization. The excess beyond the unit dose, in the high- region, reflects the dose fraction enhancement attributable to boron neutron capture reaction products.
In contrast to the similarities observed in the
distributions shown in
Figure 4, the dose-weighted distributions displayed in
Figure 5 exhibit significant differences. All spectra show a wide cluster of events, ranging from approximately 0.1 keV/μm to 20 keV/μm, originating from the interaction of photons with the detector walls. In the right panel of
Figure 5, the shape of the photon component remains largely unaffected by the 0.48 MeV prompt gamma rays generated during BNC reactions. This occurs because this portion of the spectrum primarily arises from photons generated in the beamline, target, moderating structures, and (n,γ) reactions taking place on the detector wall materials, particularly hydrogen and aluminum.
The main differences are visible in the neutron component, above approximately 20 keV/μm. In the measurement without boron, two distinct peaks emerge. The first peak, spanning from 20 to 200 keV/μm, is attributed to recoil protons generated in the detector walls through fast neutron elastic scattering with hydrogen nuclei or the capture reaction of thermal neutrons on nitrogen. The second peak, extending from 200 to 500 keV/μm, originates from recoil light ions, predominantly constituted by recoil carbon ions generated when fast neutrons scatter within the cathode walls of the detector.
As the concentration of 10B increases, the dose contribution above 20 keV/μm increases significantly as a result of the BNC reaction products. A substantial peak is formed with a maximum at approximately 300 keV/µm. Despite being responsible for a small fraction of all events, the BNC products make a significant contribution to the total absorbed dose when 10B is added to the cathode walls. At a 100 ppm concentration of 10B, the dose fraction corresponding to lineal energy events greater than 20 keV/μm amounts to approximately 50%.
Figure 6 reiterates the
distributions, previously shown in the right panel of
Figure 5, for the sake of enhanced visualization of the pure BNC components. In
Figure 6, the BNC components are distinctly highlighted as colored lines. These BNC components were derived by subtracting the spectrum obtained without boron from the total spectra acquired with boronated walls. The areas under the colored curves in
Figure 6 represent the relative dose enhancements resulting from the presence of
10B. In addition to examining dose enhancements, we also calculated the relative enhancement in the total number of events. Both aspects, the relative enhancement in the number of events (left axis) and the absorbed dose (right axis), are depicted in
Figure 7. This figure provides a comprehensive view of these enhancements as a function of the
10B concentration in the cathode walls. It can be observed that both the frequency and the dose contributions of BNC events are proportional to the boron concentration, as expected. Any deviations from the anticipated proportionality are consistently less than 3%, as demonstrated in the bottom panel of
Figure 7.
Figure 8 shows the pure BNC components at the various boron concentrations. The red line at 100 ppm represents the measured data at 100 ppm. For other concentrations (10, 25, and 70 ppm), the thin lines represent data directly measured, while the thick lines were derived by scaling each value of the 100 ppm line. Specifically, each data point on the thick lines was calculated by multiplying the corresponding value of the 100 ppm line by the ratio of the actual boron concentration (X-ppm) to 100 ppm.
The agreement between the directly measured distributions (thin line) and the ones derived from the 100 ppm data (thick line) is excellent. The key point is that both the dose components and the spectral distribution at specific boron concentrations can be accurately derived from measurements at a single concentration, such as 100 ppm.
Figure 9 depicts a comparison of the BNC component measured in this work at a simulated site size of 1 µm with the corresponding component measured and calculated by Wuu at a 2 µm site [
6] and by Kota [
10] and Burmeister at a 0.5 µm site [
11]. The agreement between the curves is very good, and small discrepancies are consistent with the variations in site sizes, gas, and shape of the sensitive volume (SV).
The three main relative dose components of the investigated radiation field, namely
Dph/
Dtot (relative photon component),
Dn/
Dtot (relative neutron component), and
DBNC/
Dtot (relative BNC component), at various boron concentrations, are reported in
Table 1.
Spectral
distributions were derived from the 100 ppm data for boron concentrations of 8.5 ppm and 30 ppm, representing typical average concentrations in BNCT for healthy and tumoral cells, respectively. These distributions are presented in
Figure 10, along with the distribution without boron. The right panel of
Figure 10 displays dose distributions weighted by the Tilikidis weighting function [
25]. Application of the weighting function enhances the impact of the BNC component compared to the photon component. The absorbed dose, normalized to a nominal dose of 1 Gy delivered in the case of no boron enrichment, RBE values calculated using Equation (3), and the biological-weighted dose are reported in
Table 2 for various boron concentrations.
It is worth noting that higher RBE values could potentially be attained by reducing the gamma component using appropriate shielding in the MUNES beam-shaping assembly.
Figure 10 illustrates that a differential boron concentration of 8.5 ppm in healthy tissue and 30 ppm in the tumor leads to a dose enhancement for cancer cells of approximately 14%. This enhancement is primarily attributed to high linear energy transfer (LET) alpha particles and Li ions, which have larger relative biological effectiveness (RBE) values. As a result, the RBE-weighted dose experiences a significant increase of 33%, playing a pivotal role in the curative effect of boron neutron capture therapy (BNCT).
The increase in the RBE-weighted dose could be further amplified by minimizing the gamma and fast neutron components, as these are not selectively targeted to cancerous tissue. In fact, the enhancement, confined to the region beyond 20 keV/µm, reaches a substantial 68%. It is important to note that the overall extent of enhancement depends on the contribution of the BNC component to the total dose—the higher the contribution of the BNC component, the greater the enhancement due to the selective delivery of boron. As highlighted in the IAEA report on BNCT [
3], it is crucial to maintain control over radiation field components that cause non-selective dose absorption.
It is important to note that microdosimetry, performed with a homogeneous boron distribution in the cathode walls, represents a simplified version of the real scenario, where the micron-scale distribution of boron could be non-uniform. As highlighted by Green [
30] and demonstrated through Monte Carlo simulations by Sato et al. [
8], intra- and inter-cellular heterogeneity in
10B distribution significantly impacts the biological effectiveness of boron neutron capture therapy (BNCT). Despite not precisely capturing the effects of a heterogeneous distribution, microdosimetry still offers valuable insights into the radiation field and the average impact of boron enrichment.
Furthermore, the microdosimetric characterization conducted using a gas detector with boron-enriched cathode walls reflects a scenario in which boron atoms are primarily externally delivered to the sensitive micrometric target. Even when working with boronated gas, the situation does not change significantly due to the low density of the gas compared to the walls. To explore a scenario where boron is included within the sensitive target, Monte Carlo simulations can be employed.
4. Conclusions
In this study, microdosimetric measurements were carried out using an avalanche-confinement tissue-equivalent proportional counter (TEPC), a specialized detector with interchangeable cathodes. Opting for this specific choice of TEPC provides the advantage that, aside from the boron content, all other characteristics of the detector remain exactly the same, allowing for a more controlled data processing.
Propane was used to fill the gas cavity at a pressure that simulated a 1 μm site size. The cathode walls were doped with varying concentrations of 10B, ranging from 0 to 100 ppm. Pairwise measurements were performed, both with and without boron, to distinguish and isolate the gamma, neutron, and pure BNC components. We indirectly verified the nominal 10B concentration, observing deviations from the nominal values of less than 3%. Additionally, we developed a robust procedure to extract the contribution of boron neutron capture (BNC) reactions for arbitrary 10B concentrations. This experimental methodology allows for the use of microdosimetric measurements performed at an arbitrary boron concentration to predict the average effectiveness of boron uptake at any other concentration.
With the exception of publications from our research group at LNL, only the works of Wuu, Kota, and Burmeister provide experimental results that can be directly compared with the measurements conducted in this study, but the direct comparison is limited with regard to the boron neutron capture (BNC) component. This limitation arises because the radiation fields were not the same, and components other than the BNC are strongly dependent on the radiation field composition and detector characteristics (e.g., wall thickness). The comparison with the BNC components measured by Wuu, Kota, and Burmeister is very good, with small discrepancies that are consistent with the different experimental conditions.
Despite the limitations relative to the boron distribution within and around the biological target, which were mentioned in the discussion, the microdosimetric approach provides valuable insights into the biological effects of BNCT on cancerous and healthy tissues, contributing to the development of innovative treatment strategies. Potential applications of microdosimetry include, for instance, the implementation of experimental microdosimetric spectra, measured at different depths in phantom, as input data of advanced treatment planning [
31,
32].
It is crucial to emphasize that the microdosimetric component of boron neutron capture (BNC), measured using the TEPC method, corresponds to the cellular effect when 10B atoms are situated in the tissue surrounding the biological sensitive target, rather than within it. Since the BNC dose is released inside the cell by two ions emitted simultaneously at an angle of 180°, the TEPC, by design, captures ionization events resulting from only one of the two ions produced in the A-150 walls. Consequently, the event size measured by the TEPC is generally smaller than the event size produced by a BNC reaction inside the biological target. To further explore the impact of different boron atom placements within biological tissue at micrometer scale, including a heterogeneous distribution, we recommend conducting Monte Carlo simulations. TEPC measurements can serve as a valuable tool to validate the Monte Carlo model.